<?xml version="1.0" encoding="UTF-8"?>
<p id="p0080">Preliminary clinical data on LPV/RTV therapy in patients with COVID-19 in China and Singapore have suggested mixed results.
 <xref rid="bib30" ref-type="bibr">30</xref>, 
 <xref rid="bib31" ref-type="bibr">31</xref>, 
 <xref rid="bib32" ref-type="bibr">32</xref> Two retrospective studies of 97 and 42 patients found that messenger RNA conversion time was correlated with hospital length of stay in LPV/RTV treatment groups (P=.0215 and P=.012),
 <xref rid="bib33" ref-type="bibr">
  <sup>33</sup>
 </xref> and patients receiving LPV/RTV, arbidol, and interferon had a shorter time to return to normal body temperature (P=.0364) and laboratory values.
 <xref rid="bib34" ref-type="bibr">
  <sup>34</sup>
 </xref> Triple combination therapy using LPV/RTV and interferon Î²-1b in an open-label randomized trial of 86 patients resulted in a shorter median number of days to viral clearance (7 vs 12 (P=.0010) in patients treated with only LPV/RTV).
 <xref rid="bib35" ref-type="bibr">
  <sup>35</sup>
 </xref> Conversely, separate retrospective analyses of 134 and 50 patients receiving LPV/RTV, arbidol, or no antiviral therapy revealed no improvement in symptoms or viral clearance from treatment (P&gt;.05).
 <xref rid="bib36" ref-type="bibr">
  <sup>36</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib37" ref-type="bibr">
  <sup>37</sup>
 </xref> A 199-patient RCT of LPV/RTV in patients with severe COVID-19 also resulted in no benefit in time to clinical improvement (P=.09) or viral RNA load compared with controls but did report reduced intensive care unit (-5 days, 95% confidence interval, -9 to 0) (ICU) length of stay.
 <xref rid="bib38" ref-type="bibr">
  <sup>38</sup>
 </xref> The results of an RCT comparing treatment with LPV/RTV and arbidol in 86 patients with mild/moderate COVID-19 indicated little benefit in clinical outcomes
 <xref rid="bib39" ref-type="bibr">
  <sup>39</sup>
 </xref> as did a randomized trial in 22 patients comparing LPV/RTV with chloroquine (CQ).
 <xref rid="bib40" ref-type="bibr">
  <sup>40</sup>
 </xref> A study of LPV/RTV pharmacokinetic properties in 8 patients with COVID-19 suggested that current doses are likely 60- to 120-fold too low at trough to achieve EC
 <sub>50</sub> concentrations,
 <xref rid="bib41" ref-type="bibr">
  <sup>41</sup>
 </xref> perhaps explaining the overall lack of effect seen in studies to date.
</p>
